

Peter Nickerson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5933748/publications.pdf>

Version: 2024-02-01

144
papers

13,713
citations

31976

53
h-index

21540

114
g-index

150
all docs

150
docs citations

150
times ranked

8470
citing authors

#	ARTICLE	IF	CITATIONS
1	The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. American Journal of Transplantation, 2022, 22, 761-771.	4.7	41
2	Role of HLA molecular mismatch in clinical practice. Human Immunology, 2022, 83, 219-224.	2.4	2
3	Effectiveness of T cell-mediated rejection therapy: A systematic review and meta-analysis. American Journal of Transplantation, 2022, 22, 772-785.	4.7	23
4	The Fourth International Workshop on Clinical Transplant Tolerance. American Journal of Transplantation, 2021, 21, 21-31.	4.7	28
5	Early surveillance biopsy utilization and management of pediatric renal allograft acute T cell-mediated rejection in Canadian centers: Observations from the PROBE multicenter cohort study. Pediatric Transplantation, 2021, 25, e13870.	1.0	6
6	Validity and utility of urinary CXCL10/Cr immune monitoring in pediatric kidney transplant recipients. American Journal of Transplantation, 2021, 21, 1545-1555.	4.7	23
7	Phospholipase A2 group XV activity during cardiopulmonary bypass surgery. Clinical Biochemistry, 2021, 88, 49-55.	1.9	1
8	Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort. American Journal of Transplantation, 2021, 21, 322-328.	4.7	31
9	A noninferiority design for a delayed calcineurin inhibitor substitution trial in kidney transplantation. American Journal of Transplantation, 2021, 21, 1503-1512.	4.7	1
10	Change in Estimated GFR and Risk of Allograft Failure in Patients Diagnosed With Late Active Antibody-mediated Rejection Following Kidney Transplantation. Transplantation, 2021, 105, 648-659.	1.0	22
11	Modest Improvements in Refractory Antibody-Mediated Rejection After Prolonged Treatment. Kidney International Reports, 2021, 6, 1397-1401.	0.8	1
12	Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney International, 2021, 100, 1012-1022.	5.2	35
13	Age and sex determine conversion from immediate-release to extended-release tacrolimus in a multicenter cohort of Canadian pediatric renal transplant recipients. Pediatric Transplantation, 2021, 25, e13959.	1.0	0
14	Early Antibody-Mediated Kidney Transplant Rejection Associated With Anti-Vimentin Antibodies: A Case Report. American Journal of Kidney Diseases, 2020, 75, 138-143.	1.9	10
15	Technical Considerations and Confounders for Urine CXCL10 Chemokine Measurement. Transplantation Direct, 2020, 6, e519.	1.6	13
16	Human leukocyte antigen molecular mismatch to risk stratify kidney transplant recipients. Current Opinion in Organ Transplantation, 2020, 25, 8-14.	1.6	22
17	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. Transplantation, 2020, 104, 911-922.	1.0	172
18	More precise donor-recipient matching: the role of eplet matching. Current Opinion in Nephrology and Hypertension, 2020, 29, 630-635.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Molecular Mismatch—the Renaissance of HLA in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1922-1925.	6.1	2
20	Defining the structural basis for human leukocyte antigen reactivity in clinical transplantation. <i>Scientific Reports</i> , 2020, 10, 18397.	3.3	6
21	PIRs mediate innate myeloid cell memory to nonself MHC molecules. <i>Science</i> , 2020, 368, 1122-1127.	12.6	92
22	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2318-2331.	4.7	437
23	What have we learned about how to prevent and treat antibody-mediated rejection in kidney transplantation?. <i>American Journal of Transplantation</i> , 2020, 20, 12-22.	4.7	29
24	Evidence for the alloimmune basis and prognostic significance of Borderline T cell–mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2499-2508.	4.7	46
25	Activity-based protein profiling guided identification of urine proteinase 3 activity in subclinical rejection after renal transplantation. <i>Clinical Proteomics</i> , 2020, 17, 23.	2.1	3
26	Donation after circulatory determination of death in western Canada: a multicentre study of donor characteristics and critical care practices. <i>Canadian Journal of Anaesthesia</i> , 2020, 67, 521-531.	1.6	8
27	Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. <i>American Journal of Transplantation</i> , 2020, 20, 2652-2668.	4.7	70
28	Activity-based Protein Profiling Approaches for Transplantation. <i>Transplantation</i> , 2019, 103, 1790-1798.	1.0	4
29	Hyperacute Antibody-mediated Rejection Associated With Red Blood Cell Antibodies. <i>Transplantation Direct</i> , 2019, 5, e477.	1.6	3
30	Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts. <i>American Journal of Transplantation</i> , 2019, 19, 1730-1744.	4.7	19
31	HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. <i>American Journal of Transplantation</i> , 2019, 19, 1708-1719.	4.7	130
32	Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients. <i>BMJ Open</i> , 2019, 9, e024908.	1.9	15
33	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. <i>American Journal of Transplantation</i> , 2018, 18, 1604-1614.	4.7	205
34	Carpe diem—Time to transition from empiric to precision medicine in kidney transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 1615-1625.	4.7	25
35	A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity. <i>Transplantation</i> , 2018, 102, 1338-1343.	1.0	79
36	Meeting report: FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients. <i>American Journal of Transplantation</i> , 2018, 18, 564-573.	4.7	38

#	ARTICLE	IF	CITATIONS
37	Evolution of renal function and urinary biomarker indicators of inflammation on serial kidney biopsies in pediatric kidney transplant recipients with and without rejection. <i>Pediatric Transplantation</i> , 2018, 22, e13202.	1.0	15
38	Urinary CXCL10 Chemokine Is Associated With Alloimmune and Virus Compartment-Specific Renal Allograft Inflammation. <i>Transplantation</i> , 2018, 102, 521-529.	1.0	32
39	Pre-transplant AT 1 R antibodies correlate with early allograft rejection. <i>Transplant Immunology</i> , 2018, 46, 29-35.	1.2	49
40	Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes. <i>Transplantation</i> , 2018, 102, 673-680.	1.0	44
41	Human leukocyte antigen mismatch and precision medicine in transplantation. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 500-505.	1.6	7
42	A call to actionâ€”The transplant recipientâ€™s expectation of precision in transplant medicine. <i>American Journal of Transplantation</i> , 2018, 18, 2845-2846.	4.7	3
43	Understanding Medication Nonadherence after Kidney Transplant. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2290-2301.	6.1	114
44	Urinary Metabolomics for Noninvasive Detection of Antibody-Mediated Rejection in Children After Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 2553-2561.	1.0	26
45	Subclinical Antibody-Mediated Rejection. <i>Transplantation</i> , 2017, 101, S1-S18.	1.0	6
46	HLA-A, B, DRB1, DQA1, DQB1 alleles and haplotype frequencies in Dene and Cree cohorts in Manitoba, Canada. <i>Human Immunology</i> , 2017, 78, 401-411.	2.4	10
47	Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3353-3362.	6.1	204
48	Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. <i>American Journal of Transplantation</i> , 2017, 17, 703-711.	4.7	70
49	Elevated Urinary Matrix Metalloproteinase-7 Detects Underlying Renal Allograft Inflammation and Injury. <i>Transplantation</i> , 2016, 100, 648-654.	1.0	23
50	Strategic Use of Epitope Matching to Improve Outcomes. <i>Transplantation</i> , 2016, 100, 2048-2052.	1.0	59
51	Six-Month Urinary CCL2 and CXCL10 Levels Predict Long-term Renal Allograft Outcome. <i>Transplantation</i> , 2016, 100, 1988-1996.	1.0	26
52	Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10. <i>Transplantation Direct</i> , 2016, 2, e78.	1.6	19
53	Non-Complementâ€“Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 615-625.	6.1	116
54	Vitamin D, serum 25(OH)D, LL-37 and polymorphisms in a Canadian First Nation population with endemic tuberculosis. <i>International Journal of Circumpolar Health</i> , 2015, 74, 28952.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Urinary biomarkers of renal transplant outcome. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 476-481.	1.6	16
56	The Canadian Kidney Paired Donation Program. <i>Transplantation</i> , 2015, 99, 985-990.	1.0	44
57	Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients With De Novo Donor-Specific Antibody. <i>American Journal of Transplantation</i> , 2015, 15, 2921-2930.	4.7	287
58	The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival. <i>American Journal of Transplantation</i> , 2015, 15, 2197-2202.	4.7	143
59	Begin at the Beginning to Prevent the End. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1483-1485.	6.1	7
60	Prediction of Long-term Renal Allograft Outcome By Early Urinary CXCL10 Chemokine Levels. <i>Transplantation Direct</i> , 2015, 1, e31.	1.6	13
61	Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3114-3122.	6.1	172
62	Acceptable mismatching at the class II epitope level. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 442-446.	1.6	16
63	Effect of Time on Dialysis and Renal Transplantation on Endothelial Function. <i>Transplantation</i> , 2014, 98, 1060-1068.	1.0	5
64	Elevated Urinary CCL2. <i>Transplantation</i> , 2014, 98, 39-46.	1.0	31
65	Blood donors implicated in transfusion-related acute lung injury with patient-specific HLA antibodies are more broadly sensitized to HLA antigens compared to other blood donors. <i>Transfusion</i> , 2013, 53, 518-525.	1.6	9
66	Rejection: An Integrated Response. <i>American Journal of Transplantation</i> , 2013, 13, 2239-2240.	4.7	11
67	Proteomic characterization of serine hydrolase activity and composition in normal urine. <i>Clinical Proteomics</i> , 2013, 10, 17.	2.1	24
68	Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 470-477.	1.6	60
69	Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. <i>Transplantation</i> , 2013, 95, 19-47.	1.0	679
70	Antibodies Beyond HLA. <i>American Journal of Transplantation</i> , 2013, 13, 831-832.	4.7	7
71	Class II HLA Epitope Matching—A Strategy to Minimize De Novo Donor-Specific Antibody Development and Improve Outcomes. <i>American Journal of Transplantation</i> , 2013, 13, 3114-3122.	4.7	298
72	Increased Urinary CCL2. <i>Transplantation</i> , 2013, 95, 595-602.	1.0	29

#	ARTICLE	IF	CITATIONS
73	Dietary intake of vitamin D in a northern Canadian DenÅ© First Nation community. <i>International Journal of Circumpolar Health</i> , 2013, 72, 20723.	1.2	18
74	Killer Immunoglobulin-Like Receptor (KIR) Centromeric-AA Haplotype Is Associated with Ethnicity and Tuberculosis Disease in a Canadian First Nations Cohort. <i>PLoS ONE</i> , 2013, 8, e67842.	2.5	14
75	Immune Monitoring of Kidney Allografts. <i>American Journal of Kidney Diseases</i> , 2012, 60, 629-640.	1.9	38
76	Vitamin D in a Northern Canadian First Nation Population: Dietary Intake, Serum Concentrations and Functional Gene Polymorphisms. <i>PLoS ONE</i> , 2012, 7, e49872.	2.5	40
77	Serum Creatinine Measurement Immediately After Cardiac Surgery and Prediction of Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , 2012, 59, 196-201.	1.9	73
78	Evolution and Clinical Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney Transplant. <i>American Journal of Transplantation</i> , 2012, 12, 1157-1167.	4.7	817
79	Worldwide variability in deceased organ donation registries. <i>Transplant International</i> , 2012, 25, 801-811.	1.6	48
80	Effect of Vitamin D Supplementation on Mycobacterium tuberculosis-Induced Innate Immune Responses in a Canadian DenÅ© First Nations Cohort. <i>PLoS ONE</i> , 2012, 7, e40692.	2.5	30
81	Housing conditions in 2 Canadian First Nations communities. <i>International Journal of Circumpolar Health</i> , 2011, 70, 141-153.	1.2	41
82	Validation of Urinary CXCL10 As a Marker of Borderline, Subclinical, and Clinical Tubulitis. <i>Transplantation</i> , 2011, 92, 878-882.	1.0	68
83	The potential influence of KIR cluster profiles on disease patterns of Canadian Aboriginals and other indigenous peoples of the Americas. <i>European Journal of Human Genetics</i> , 2011, 19, 1276-1280.	2.8	18
84	Urinary Hecpidin-25 and Risk of Acute Kidney Injury Following Cardiopulmonary Bypass. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2340-2346.	4.5	58
85	Long-Term Medical Outcomes Among Aboriginal Living Kidney Donors. <i>Transplantation</i> , 2010, 90, 401-406.	1.0	30
86	Early Urinary CCL2 is Associated With the Later Development of Interstitial Fibrosis and Tubular Atrophy in Renal Allografts. <i>Transplantation</i> , 2010, 90, 394-400.	1.0	52
87	The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline. <i>Transfusion Medicine Reviews</i> , 2010, 24, S7-S27.	2.0	96
88	Response to Proinflammatory Events and HLA Antibodies. <i>American Journal of Transplantation</i> , 2010, 10, 957-957.	4.7	0
89	Two cases of platelet transfusion refractoriness associated with antiâ€CD36. <i>Transfusion</i> , 2010, 50, 2638-2642.	1.6	14
90	Proteomic Portrayal of Transplant Pathologies. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 236-238.	6.1	5

#	ARTICLE	IF	CITATIONS
91	Proinflammatory Events and HLA Antibodies: Nothing to Sneeze At. American Journal of Transplantation, 2009, 9, 1971-1972.	4.7	1
92	Mass Spectrometry-Based Proteomic Analysis of Urine in Acute Kidney Injury Following Cardiopulmonary Bypass: A Nested Case-Control Study. American Journal of Kidney Diseases, 2009, 53, 584-595.	1.9	176
93	Post-transplant monitoring of renal allografts: are we there yet?. Current Opinion in Immunology, 2009, 21, 563-568.	5.5	22
94	Factors Associated With Progression of Interstitial Fibrosis in Renal Transplant Patients Receiving Tacrolimus and Mycophenolate Mofetil. Transplantation, 2009, 88, 897-903.	1.0	24
95	The Impact of Immune Gene Polymorphisms in Kidney and Liver Transplantation. Clinics in Laboratory Medicine, 2008, 28, 455-468.	1.4	15
96	Proteomics and Renal Transplantation: Searching for Novel Biomarkers and Therapeutic Targets. , 2008, 160, 65-75.		22
97	Functional Gene Polymorphisms in Canadian Aboriginal Populations with High Rates of Tuberculosis. Journal of Infectious Diseases, 2008, 198, 1175-1179.	4.0	65
98	The Use of IVIG for Solid Organ Transplantation: An Evidence Based Practice Guideline. Blood, 2008, 112, 4666-4666.	1.4	0
99	Detection of Subclinical Tubular Injury After Renal Transplantation: Comparison of Urine Protein Analysis With Allograft Histopathology. Transplantation, 2007, 84, 104-112.	1.0	85
100	Proteomics of Human Urine. , 2007, , 225-268.		0
101	Impact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: Interaction with IL-10 gene polymorphisms. Hepatology, 2007, 45, 623-630.	7.3	56
102	Biologically Variable Bypass Reduces Enzymuria After Deep Hypothermic Circulatory Arrest. Annals of Thoracic Surgery, 2006, 82, 1480-1488.	1.3	10
103	The Routine Use of High-Resolution Immunological Screening of Recipients of Primary Deceased Donor Kidney Allografts Is Cost-Effective. Transplantation, 2006, 81, 1278-1284.	1.0	9
104	Developing a tool for noninvasive monitoring of renal allografts. Expert Review of Proteomics, 2006, 3, 497-509.	3.0	18
105	The Relative Importance of Cytokine Gene Polymorphisms in the Development of Early and Late Acute Rejection and Six-Month Renal Allograft Pathology. Transplantation, 2005, 79, 836-841.	1.0	58
106	Detection of a single nucleotide polymorphism in the IL-6 promoter region of ancient nuclear DNA. Infection, Genetics and Evolution, 2005, 5, 117-122.	2.3	1
107	Proteomic-Based Identification of Cleaved Urinary Î²2-microglobulin as a Potential Marker for Acute Tubular Injury in Renal Allografts. American Journal of Transplantation, 2005, 5, 729-738.	4.7	199
108	The Role of Cytokine Gene Polymorphisms in Determining Disease Susceptibility and Phenotype in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2005, 100, 1134-1142.	0.4	90

#	ARTICLE	IF	CITATIONS
109	Leukocyte Reduction of Red Blood Cell Transfusions Does not Decrease Allosensitization Rates in Potential Kidney Transplant Candidates. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 818-824.	6.1	67
110	Proteomic-Based Detection of Urine Proteins Associated with Acute Renal Allograft Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 219-227.	6.1	281
111	Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. <i>Kidney International</i> , 2004, 65, 323-332.	5.2	304
112	Evolution of HLA Antibody Detection: Technology Emulating Biology. <i>Immunologic Research</i> , 2004, 29, 041-054.	2.9	101
113	Pre-Transplant Assessment of Donor-Reactive, HLA-Specific Antibodies in Renal Transplantation: Contraindication vs. Risk. <i>American Journal of Transplantation</i> , 2003, 3, 1488-1500.	4.7	319
114	Heightened Peripheral Blood Lymphocyte CD69 Expression is Neither Sensitive nor Specific as a Noninvasive Diagnostic Test for Renal Allograft Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 226-233.	6.1	14
115	Computerized Image Analysis of Sirius Red Stained Renal Allograft Biopsies as a Surrogate Marker to Predict Long-Term Allograft Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1662-1668.	6.1	175
116	Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. <i>Transplantation</i> , 2003, 76, 1498-1502.	1.0	99
117	Reproducibility of the Banff schema in reporting protocol biopsies of stable renal allografts. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1081-1084.	0.7	67
118	Long-term allograft surveillance: the role of protocol biopsies. <i>Current Opinion in Urology</i> , 2001, 11, 133-137.	1.8	10
119	Neointimal and Tubulointerstitial Infiltration by Recipient Mesenchymal Cells in Chronic Renal-Allograft Rejection. <i>New England Journal of Medicine</i> , 2001, 345, 93-97.	27.0	259
120	Flow Cytometric Crossmatching in Primary Renal Transplant Recipients with a Negative Anti-Human Globulin Enhanced Cytotoxicity Crossmatch. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2807-2814.	6.1	190
121	Cytokines and Their Receptors as Therapeutic Targets. , 2001, , 81-99.		0
122	PROTOCOL BIOPSY PREDICTION OF LONG TERM RENAL ALLOGRAFT SURVIVAL: USING COMPUTERIZED IMAGE ANALYSIS OF SIRIUS RED STAINED FIBROSIS.. <i>Transplantation</i> , 2000, 69, S363.	1.0	3
123	Protocol biopsies in the management of renal allograft recipients. <i>Current Opinion in Nephrology and Hypertension</i> , 2000, 9, 615-619.	2.0	18
124	Subclinical acute rejection: Is it a cause of chronic rejection in renal transplantation?. <i>Transplantation Reviews</i> , 2000, 14, 131-137.	2.9	5
125	Does subclinical rejection contribute to chronic rejection in renal transplant patients?. <i>Clinical Transplantation</i> , 1999, 13, 441-446.	1.6	52
126	Quantitation of allograft fibrosis and chronic allograft nephropathy. <i>Pediatric Transplantation</i> , 1999, 3, 257-270.	1.0	38

#	ARTICLE	IF	CITATIONS
127	The Banff 97 working classification of renal allograft pathology. <i>Kidney International</i> , 1999, 55, 713-723.	5.2	2,817
128	Clinical Rejection Is Distinguished from Subclinical Rejection by Increased Infiltration by a Population of Activated Macrophages. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1582-1589.	6.1	122
129	Effect of Increasing Baseline Immunosuppression on the Prevalence of Clinical and Subclinical Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1801-1805.	6.1	79
130	Protocol biopsies in renal transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 1998, 7, 691-694.	2.0	36
131	INTERFERON- γ RECEPTOR SIGNALING IS NOT REQUIRED IN THE EFFECTOR PHASE OF THE ALLOIMMUNE RESPONSE1. <i>Transplantation</i> , 1998, 65, 1649-1652.	1.0	19
132	MATCHING FOR PRIVATE OR PUBLIC HLA EPITOPES REDUCES ACUTE REJECTION EPISODES AND IMPROVES TWO-YEAR RENAL ALLOGRAFT FUNCTION. <i>Transplantation</i> , 1998, 66, 38-43.	1.0	47
133	IL-2 and IL-4 double knock-out mice reject islet allografts: A role for novel T-cell growth factors?. <i>Transplantation Proceedings</i> , 1997, 29, 1083-1084.	0.6	10
134	Interleukin-15 gene transcripts are present in rejecting islet allografts. <i>Transplantation Proceedings</i> , 1997, 29, 1077-1078.	0.6	20
135	MANIPULATION OF CYTOKINE NETWORKS IN TRANSPLANTATION. <i>Transplantation</i> , 1997, 63, 489-494.	1.0	97
136	CTLA4Ig ATTENUATES ACCELERATED REJECTION (PRESENSITIZATION) IN THE MOUSE ISLET ALLOGRAFT MODEL1. <i>Transplantation</i> , 1997, 64, 172-175.	1.0	17
137	Prolonged islet allograft acceptance in the absence of interleukin 4 expression. <i>Transplant Immunology</i> , 1996, 4, 81-85.	1.2	55
138	The Th1/Th2 paradigm and the allograft response. <i>Current Opinion in Immunology</i> , 1996, 8, 688-693.	5.5	251
139	Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. <i>Journal of Immunology</i> , 1995, 155, 1165-74.	0.8	81
140	IL-2 knockout recipient mice reject islet cell allografts. <i>Journal of Immunology</i> , 1995, 155, 489-98.	0.8	125
141	Cytokines and the Th1/Th2 paradigm in transplantation. <i>Current Opinion in Immunology</i> , 1994, 6, 757-764.	5.5	233
142	High serum levels of interleukin-6 in renal transplant recipients with monoclonal gammopathies. <i>Transplantation</i> , 1994, 58, 382-6.	1.0	3
143	Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. <i>Journal of Immunology</i> , 1993, 150, 1093-104.	0.8	92
144	SLEEP APNOEA PATIENTS HAVE MORE AUTOMOBILE ACCIDENTS. <i>Lancet, The</i> , 1987, 330, 447.	13.7	216